Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

Blood

Volumn 111, Issue 6, 2008, Pages 3155-3162

  Alici, Evren ^a   Sutlu, Tolga ^a   Björkstrand, Bo ^a   Gilljam, Mari ^a   Stellan, Birgitta ^a   Nahi, Hareth ^a   Quezada, Hernan Concha ^a   Gahrton, Gösta ^a   Ljunggren, Hans Gustaf ^a   Dilber, M Sirac ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; CYTOKINE; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS NATURAL KILLER CELL; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL EXPANSION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DEGRANULATION; EX VIVO STUDY; FEMALE; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; BIOSYNTHESIS; CELL SEPARATION; CELL SURVIVAL; CULTURE TECHNIQUE; CYTOLOGY; IMMUNOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED; PHENOTYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CELL CULTURE TECHNIQUES; CELL SEPARATION; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHENOTYPE; RECEPTORS, IMMUNOLOGIC;

EID: 42449160619     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-110312     Document Type: Article

References (46)

1. Kuehl WM. Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
2. Gahrton G, Tura S. Ljungman P. et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N EnglJ Med. 1991;325:1267-1273.
3. Lokhorst HM. Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031-3037.
4. Gahrton G. Progress in hematopoietic stem cell transplantation in multiple myeloma. Curr Opin Hematol. 2005;12:463-470.
5. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105: 4532-4539.
6. Davies FE. Raje N. Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
7. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410-451.
8. Kaufmann H, Urbauer E. Ackermann J. Huber H, Drach J. Advances in the biology and therapeutic management of multiple myeloma. Ann Hematol. 2001;80:445-451.
9. Alici E, Bjorkstrand B, Treschow A, et al. Longterm follow-up of gene-marked GD34+ cells after autologous stem cell transplantation for multiple myeloma. Cancer Gene Ther. 2007;14:227-232.
10. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse: I. cytotoxic cells with specificity for mouse Moloney leukemia cells: specificity and distribution according to genotype. EurJ Immunol. 1975;5:112-117.
11. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
12. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev. 2006;214:73-91.
13. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7:329-339.
14. Carlens S, Gilljam M, Chambers BJ, et al. Anew method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol. 2001;62:1092-1098.
15. Heiskala MK, Carpen O, Saksela E, Timonen T. Mechanism of cell contact-mediated inhibition of natural killer activity. J Immunol. 1987; 139:1414-1418.
16. Stark S, Watzl C. 2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int Immunol. 2006;18: 241-247.
17. Carlsten M, Bjorkstrom NK, Norell H, et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007;67:1317-1325.
18. Carbone E, Neri P, Mesuraca M, et al. HLAclass I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105:251-258.
19. Forte P, Lilienfeld BG, Baumann BC, Seebach JD. Human NK cytotoxicity against porcine cells is triggered by NKp44 and NKG2D. J Immunol. 2005;175:5463-5470.
20. Sugita K, Torimoto Y, NojimaY, Daley JF. Schlossman SF, Morimoto C. The 1A4 molecule (CD27) is involved in T cell activation. J Immunol. 1991;147:1477-1483.
21. Kuku I, Bayraktar MR, Kaya E, et al. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma. Mediators Inflamm. 2005;2005:171-174.
22. Alter G, Malenfant JM, Altfeld M. CD107a asa functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294: 15-22.
23. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107:159-166.
24. Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003;102:1435-1442.
25. Zinneman HH, Hall WH. Recurrent pneumonia in multiple myeloma and some observations on immunologic response. Ann Intern Med. 1954:41: 1152-1163.
26. Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-betai and interleukin-10. Blood. 2001;98:2992-2998.
27. Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006;107:301-304.
28. Beyer M, Kochanek M, GieseT, et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood. 2006;107:3940-3949.
29. Frohn C, Hoppner M, Schlenke P, Kirchner H, Koritke P. Luhm J. Anti-myeloma activity of natural killer lymphocytes. BrJ Haematol. 2002;119: 660-664.
30. Uchida A. Yagita M. Sugiyama H, Hoshino T, Moore M. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int J Cancer. 1984;34:375-381.
31. Bianchi A, Omede P. Attisano C, et al. Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha 2b therapy in multiple myeloma patients with low tumor mass. Haematologica. 1991;76:383-388.
32. Gahrton G. Durie BG. Samson D. Multiple Myeloma and Related Disorders. London, United Kingdom: Arnold; 2004.
33. Matsuzaki H, Kagimoto T, Oda T, Kawano F, Takatsuki K. Natural killer activity and antibodydependent cell-mediated cytotoxicity in multiple myeloma. Jpn J Clin Oncol. 1985;15:611-617.
34. Ogmundsdottir HM. Natural killer cell activity in patients with multiple myeloma. Cancer Detect Prev. 1988;12:133-143.
35. Nielsen H, Nielsen HJ. Tvede N, et al. Immune dysfunction in multiple myeloma: reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. APMIS. 1991;99:340-346.
36. Fauriat C. Mallet F. Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia. 2006;20:732-733.
37. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneid HCT. Blood. 2007;109:5058-5061.
38. Grau R, Lang KS, Wernet D. et al. Cytotoxic activity of natural killer cells lacking killer-inhibitory receptors for self-HLA class I molecules against autologous hematopoietic stem cells in healthy individuals. Exp Mol Pathol. 2004;76:90-98.
39. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223.
40. Fuchs A. Colonna M. The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol. 2006;16: 359-366.
41. Shibuya A. Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 199;4:573-581.
42. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006; 176:1517-1524.
43. Frohn C, Doehn C, Durek C, et al. Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma. J Immunother (1997). 2000;23:499-504.
44. Passweg JR. Tichelli A, Meyer-Monard S. et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18:1835-1838.
45. Ishikawa E, Tsuboi K, Saijo K, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004;24:1861-1871.
46. Miller JS. Soignier Y. Panoskaltsis-Mortari A. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051-3057.